Sites

On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum.

We have cancelled our webinar “After the Compliance Date: Revised Common Rule FAQs,” which was originally scheduled for February 28.

If your research must comply with the revised Common Rule, you’ll need to update the way you write ICFs to meet the new requirements.

While many US researchers are aware of the coming Common Rule changes, not everyone is sure whether they will need to comply with the revised regulations.

Given the growth in gene therapy research, sponsors, CROs and sites have become increasingly curious about the requirements to be able to conduct such studies.

The Advarra team is proud to announce that all major integration activities are now complete.

Let’s take a look at the basics of what each program does and does not do for patients seeking to access investigational therapies.

The Advarra team has worked to fully integrate our processes and policies to provide clients with unified capabilities and support for IRB, IBC and global research quality and compliance consulting services.

The following FAQ expands upon previous FAQs we’ve published and provides additional insight into the integration process.

Clinical research continues to grow throughout the world, with researchers looking outside the US for new and diverse subject populations to help develop and improve investigational therapies. Lauri Carlile, VP of Operations at Advarra, discusses the basics of ex-US research ethics review for US-based researchers.

New to clinical research? Learn the meaning of common industry acronyms and abbreviations including eCRF, IIT, PI, TMF, and more.

Since November 2017, the Advarra team (formerly Chesapeake IRB and Schulman IRB) has been working to integrate our process and policies. We are committed to being transparent throughout this integration, so we've assembled the following FAQ to keep you updated.